BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Nolato AB ( NOLA-B.ST) Acquires Cope Allman Jaycare for SEK 179 Million


4/11/2012 7:46:45 AM

TOREKOV, Sweden--(BUSINESS WIRE)-- Regulatory News: Acquisition of British pharmaceutical packaging company results in a stronger customer base and geographic expansion for Nolato Medical (STO:NOLAB)

As part of the Nolato Group’s strategic expansion within medical technology and pharmaceuticals, Nolato has acquired the British company Cope Allman Jaycare for an initial purchase price of SEK 179 million (enterprise value) and a deferred consideration based on earnings up to and including the first quarter of 2014.

Cope Allman Jaycare, which manufactures plastic pharmaceutical packaging, has annual sales of around SEK 270 million. Its customers include a number of major international pharmaceutical companies. The company will be consolidated from 1 April, and will have a positive effect on Nolato’s earnings per share 2012.

“Following the acquisition of the US company Contour Plastics, we have worked to add an acquisition in Western Europe,” says Hans Porat, President and CEO of Nolato. “Cope Allman Jaycare is a well-managed company, and is a good fit for our growth strategy.”

Cope Allman Jaycare has a history within pharmaceutical packaging dating back to 1958, and is expected to record sales for 2012 of around SEK 270 million, with a pro forma EBITDA margin of approximately 14%. The company has 270 employees at its plants in Portsmouth and Newcastle, England.

“Nolato already has a strong position in the Scandinavian pharmaceutical packaging market,” adds Christer Wahlquist, President of Nolato Medical. “This acquisition gives us a local presence in the UK, which is an important part of the global pharma­ceutical industry. It also opens doors with a large number of leading international pharmaceutical companies which are existing customers of Cope Allman Jaycare.”

The company is being acquired from its current management, which will remain with the business.

Following the acquisition, Nolato will continue to have a strong financial position, with an equity/assets ratio of approximately 47%.

The Nolato Group is a high-tech developer and manufacturer of polymer product systems for leading customers in medical technology, telecom, hygiene, automotive products and other ­selected industrial sectors. Nolato’s shares are quoted on the Nasdaq OMX Nordic Exchange, Stockholm Mid Cap, Industrials. www.nolato.com

Nolato AB discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 8.25 am on 11 April 2012.

This information was brought to you by Cision http://www.cisionwire.com

Contact:

Hans Porat, CEO,

+46 431 442294

or

Per-Ola Holmström, CFO,

+46 431 442293


Read at BioSpace.com


Nolato AB
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->